Edward Nash

Stock Analyst at Canaccord Genuity

(3.64)
# 838
Out of 4,650 analysts
69
Total ratings
46.67%
Success rate
8.38%
Average return

Stocks Rated by Edward Nash

Travere Therapeutics
Sep 30, 2024
Maintains: Buy
Price Target: $23$22
Current: $18.37
Upside: +19.76%
Ventyx Biosciences
Aug 12, 2024
Maintains: Buy
Price Target: $15$14
Current: $2.39
Upside: +485.77%
Corcept Therapeutics
Jul 31, 2024
Maintains: Buy
Price Target: $38$78
Current: $48.21
Upside: +61.79%
Verona Pharma
Jul 22, 2024
Maintains: Buy
Price Target: $35$37
Current: $33.67
Upside: +9.89%
Cardiol Therapeutics
May 23, 2024
Maintains: Buy
Price Target: $6$8
Current: $1.83
Upside: +337.16%
Akero Therapeutics
May 13, 2024
Maintains: Buy
Price Target: $59$56
Current: $31.73
Upside: +76.49%
Inventiva
Apr 8, 2024
Maintains: Buy
Price Target: $12$20
Current: $2.68
Upside: +646.27%
Rani Therapeutics Holdings
Mar 27, 2024
Maintains: Buy
Price Target: $21$9
Current: $2.34
Upside: +284.62%
Madrigal Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $338$377
Current: $217.79
Upside: +73.10%
Theratechnologies
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $1.23
Upside: +550.67%
Maintains: Buy
Price Target: $16$17
Current: $5.68
Upside: +199.30%
Initiates: Buy
Price Target: $48
Current: $14.72
Upside: +226.09%
Maintains: Hold
Price Target: $3$2
Current: $2.29
Upside: -12.66%
Downgrades: Hold
Price Target: $900$180
Current: $3.66
Upside: +4,818.03%
Maintains: Buy
Price Target: $80$82
Current: $52.80
Upside: +55.30%
Maintains: Hold
Price Target: $120$80
Current: $7.76
Upside: +930.93%
Initiates: Buy
Price Target: $48
Current: $6.42
Upside: +647.66%
Initiates: Buy
Price Target: $650
Current: $6.57
Upside: +9,793.46%